Almac Launch XCEL Array: The Optimum Platform for Biomarker Discovery
Almac
announced the launch of XCEL™ array, a biomarker discovery platform that enables the identification of biomarkers within multiple disease areas.
Almac’s propriety XCEL™ array contains 92,000 transcripts, and the technology is optimised for use with Formalin Fixed Paraffin Embedded (FFPE) tissue.
XCEL™ array is a high density transcriptome based microarray based on the industry standard Affymetrix GeneChip® platform. The content of XCEL has been derived from high quality proprietary sequence data, as well as mining public gene expression and sequence databases. The design methodologies of the array are derived from validated methods derived for Almac’s range of cancer DSA® (Disease Specific Arrays).
The substantial content on Almac’s XCEL™ array ensures that the platform technology is ideally suited for research in cross-disease areas.
President and Managing Director of Almac Diagnostics, Professor Paul Harkin commented, “Our XCEL™ array provides a platform for the discovery of biomarkers in a range of diseases and where cross disease compatibility is important. This array becomes an important part of our solutions for the delivery of personalised medicine”
The XCEL™ array adds to Almac’s portfolio of proprietary discovery arrays which include; Breast DSA®, Colorectal DSA®, Lung Cancer DSA®, Ovarian Cancer DSA® and Prostate Cancer DSA®.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
